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Abstract
Background: The stiff person syndrome (SPS) is a rare disorder characterized by muscular rigidity and stiffness.
Case presentations: We describe an SPS patient presenting with longstanding fatigue and electrophysiological
evidence of presynaptic neuromuscular transmission defect, who responded to administration of pyridostigmine.
In contrast, no electrophysiolgical evidence of neuromuscular transmission defect was demonstrated in 2 other
SPS patients without fatigue symptoms.
Conclusions: Our findings suggest that glutamic acid decarboxylase (GAD) antibodies may play a role in presynaptic
neuromuscular transmission defect of SPS patients with fatigue.
Keywords: Stiff person syndrome, Fatigue, Presynaptic, Neuromuscular transmission
Background
The stiff person syndrome (SPS) is a rare disorder
characterized by progressive rigidity and stiffness. SPS
characteristically affects the truncal or axial muscles,
and may lead to chronic pain, spasms, postural deform-
ities and impaired motility. Variants of SPS, including
stiff limb syndrome, jerking man syndrome and paraneo-
plastic associations have been described.
Up to 80% [1] of SPS patients have elevated glutamic
acid decarboxylase (GAD) antibodies, but its exact role
in the pathogenesis remains unclear. GAD antibody
levels generally do not correlate with disease severity [2],
nor has it been determined as the sole cause of clinical
manifestations.
GAD is a presynaptic molecule which exists in 2 main
isoforms: GAD67 and GAD65. The latter is of interest
as it is localized to the nerve terminals and synthesizes
gamma-aminobutyric acid (GABA) for neurotransmis-
sion [3]. Most SPS patients with GAD antibodies also
have antibodies which inhibit GABA-receptor-associated
protein, leading to GABA functional impairment and
hence the clinical features [4].
The occurrence of fatigue has been reported in SPS [5]
but may be overshadowed by other muscular complaints.
Neuromuscular fatigue is well correlated with neuro-
muscular transmission defect. This may be postsynaptic,
as in myasthenia gravis, or presynaptic, as in the Lam-
bert Eaton and Miller Fisher syndromes [6, 7].
We describe an SPS patient presenting with longstand-
ing fatigue and electrophysiological evidence of pre-
synaptic neuromuscular transmission defect.
Case presentations
Patient 1
A 62-year old previously healthy Caucasian female expe-
rienced a 20 year history of pain in the neck, truncal and
limb muscles. The symptoms were exacerbated by exer-
cise and had a fluctuating course. In addition, she has
muscle cramps, stiffness and spasms which she needed
periods of rest to allow symptoms to alleviate.
Notably, she reported severe fatigue symptoms for the
same period of time, made worse with physical exertion
and mental stress. She had consulted multiple doctors
and given diagnoses, including chronic fatigue syndrome
(CFS) or myalic encephalomyelitis, and fibromyalgia.
These symptoms had severely affected her lifestyle and
can last up to several days in duration.
There were no complaints of confusion, memory loss,
seizures, vertigo, loss of appetite or weight.
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Clinical examination showed a well and alert middle-
aged woman. No signs of muscle wasting, tremor, dystonia
or fasciculations were observed. There was no obvious
muscle weakness or fatigability. Examination of cranial
nerves, cerebellar system, sensation and position sense
were unremarkable.
Nerve conduction study is not suggestive of sensori-
motor polyneuropathy. Needle electromyography per-
formed showed involuntary firing of motor units with
normal morphology at rest. During voluntary activation,
there was normal recruitment of motor units seen.
Stimulated single fiber electromyography (SFEMG) of
the orbicularis oculi was achieved using a disposable
monopolar needle electrode (TECA, Old Woking, United
Kingdom) placed 2.5 cm away from the edge of the orbicu-
laris oculi. Stimulation pulses of 0.01 ms at 10 Hz and 5 to
12 mA were administered. A 40-mm 9013K0872needle
electrode (Dantec, Skovlunde, Denmark) was inserted at
the edge of the muscle for single-fiber recordings. Filter
settings were maintained at 500 kHz to 10 kHz.
Single-fiber responses were selected on the basis of
short rise times (<300 us), clear separation from other
discharges and stability of waveform. Mean jitter was
calculated from 20 accepted single-fiber responses. All
SFEMG studies were performed on a Dantec Keypoint
EMG machine [8]. SFEMG showed a mean jitter of
27.7 μs (normal < 23), of which 13 of 42 fibers re-
corded jitter values above 30 μs.
Repetitive nerve stimulation (RNS) studiesof the ulnar
nerve was performed with right abductor digiti minimi
recording [6] at the following frequencies in random
order: 3 Hz at rest, 3 Hz post-exercise, 20 Hz and 50 Hz.
Exercise consisted of 20 s of maximal muscle contraction.
Each study was performed at 3-min intervals. The 3 Hz
RNS consisted of 10 stimuli trains, while 20 Hz and 50 Hz
RNS consisted of 30 stimuli trains. For 3 Hz RNS, negative
peak amplitude percentage decrements were compared
between the first and fourth compound muscle action
potentials (CMAP). For 20 Hz and 50 Hz RNS, percentage
increments between the first CMAP and the CMAP
with the largest amplitude were calculated. For this
patient, RNS showed amplitude decrement of −1%
(normal < − 8%) at 3 Hz, increment of +71% (normal
< 48%) at 20 Hz, and +67% at 50 Hz (normal < 52%).
Acetylcholine receptor and anti-MUSK antibody titres
were within normal limits. Autoantibody screening
showed increased antinuclear factor titre of 1/100 but
anti- DsDNA, ANCA, Anti-Ro (SSA), anti-La (SSB) and
anti-Jo-1 antibody titres were normal.
She was subsequently found to have elevated anti-
GAD titre of 19 U/mL (normal < 0.8).
She underwent CT scan of her chest, abdomen and
pelvis but no malignancy was detected. MRI of the brain
and spine performed previously were unremarkable.
In view of her religious beliefs, she declined intraven-
ous immunoglobulin (IVIg), but was administered oral
prednisolone 30 mg daily over a 6 week period. This was
effective in reducing muscle cramps and spasms. Pain
score had declined from 6 to 2 on the visual analogue
scale. To address her longstanding fatigue, a trial of pyri-
dostigmine at 60 mg three times a day over a 4 week
period resulted in significant reduction of fatigue symp-
toms. Using the Fatigue Severity Scale [9], initial scoring
of 49 declined to 28 after treatment. On a 10 point vis-
ual analogue fatigue scale, the initial score of 8 declined
to 3.5.
Patient 2
A 63-year old man presented with back pain and stiff-
ness radiating to the anterior trunk, neck and chest.
Clinically, no involuntary movements, muscle wasting,
fasciculations or tremors were noted. He was neuro-
logically normal on examination. He was extensively in-
vestigated with brain imaging, gastroscopy, colonoscopy,
CT scans of chest and abdomen which were all unre-
markable. MRI of the brain was unremarkable, but there
were mild degenerative changes in the lumbar spine. An
autoimmune screen detected elevated anti-GAD titer of
50 U/mL. EMG showed characteristic continuous nor-
mal motor unit activity at rest in the paraspinal and
shoulder girdle muscles, without myokymia or myotonic
potentials.
RNS was performed using a similar method as in Pa-
tient 1. RNS amplitude decrement of −1% at 3 Hz, incre-
ment of +31.1% at 20 Hz, and +13.1% at 50 Hz, all
within normal limits, were noted. SFEMG findings were
within normal limits.
He responded to 2 courses of IVIg administered over
5 days but did not record benefit with oral corticoste-
roids. Pain score declined from 8 to 4 after each IVIg
administration.
Patient 3
A 56-year old man complained of left lower limb stiff-
ness and cramps developing over a 2 month period,
which gradually involved the right side. Upon presenta-
tion, tendon reflexes were normal but power was diffi-
cult to assess due to stiffness. Investigations to rule out
malignancy were negative. Autoimmune testing showed
elevated anti-GAD levels of 130 U/mL (normal up to
0.8), but other antibody titres were not elevated.
EMG gain showed continuous normal motor unit
activity at rest in the paraspinal, proximal limb and
shoulder girdle muscles.
CT scans of the brain, chest, abdomen and pelvis did
not reveal space occupying lesions. Mild degenerative
changes were present in the cervical and thoracic MRI,
but brain MRI was unremarkable.
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RNS was performed using a similar method as in
Patient 1. RNS amplitude decrement of – 4.6% at 3 Hz,
increment of +9.2% at 20 Hz, and +6.2% at 50 Hz, all
within normal limits, were noted.
The stiffness responded to a 5 day course of IVIg but
he experienced a relapse, requiring a second course of
IVIg and oral corticosteroids. Upon review 8 weeks later,
he continued to improve and oral medication dosages
were reduced. Pain score declined from 8 to 3 after each
treatment.
All 3 patients had unremarkable cerebrospinal fluid
examination, without elevation of cells or protein.
Figures 1 and 2 are RNS and EMG tracings of Patient 1.
Conclusions
Our series of 3 patients highlights the findings of pre-
synaptic neuromuscular transmission defect in Patient 1,
evidenced by symptomatic response to pyridostigmine
and electrophysiological testing. In contrast, Patient 2 with
classical SPS and Patient 3 with the stiff limb syndrome
variant [10] both do not exhibit fatigue symptoms or posi-
tive electrophysiological evidence of neuromuscular trans-
mission disturbance, thus serving as negative controls.
Incremental responses to RNS are characteristic of
neuromuscular transmission defect at the presynaptic
region [11]. We have previously reported similar findings
in the Miller Fisher syndrome as a subclinical phenomenon
[7]. However, the current Patient 1 is symptomatic and
responded to pharmacological intervention. Fatigue is
seldom reported in SPS, but Teggi et al. described an SPS
patient with fatigue and recurrent vertigo who improved
with immune therapy [5]. However, it is unclear if this
patient had neuromuscular transmission disturbances.
GAD65 is important for GABA synthesis in normal
synaptic transmission. It has been shown in a Drosophila
model that GAD mutants can result in defective synaptic
transmission at the neuromuscular junction, as GAD is
specifically required in the presynaptic neuron to induce
a an appropriate postsynaptic response [12].
In SPS, it is unclear the direct pathogenic role GAD
antibodies play in its symptomatology. It has been sug-
gested that reduction of GABA-mediated inhibitory effects
leads to a pathological state of neuronal hyperexcitability.
Injection of IgG-GAD antibodies in the lumbar region in-
duced continuous motor activity of anterior horn cells [13].
In the Drosophila model [12], GAD is required in the
presynaptic neuron to induce a postsynaptic glutamate
receptor field, and the levels of postsynaptic receptors
are closely dependent on presynaptic GAD function.
Our electrophysiological findings point to a presynaptic
Fig. 1 RNS tracings of Patient 1 showing maximal amplitude increment of +71% at 20 Hz. Sweep speed and vertical gain are as shown
Fig. 2 EMG of the left deltoid of Patient 1 depicting spontaneous normal motor unit activity. Sweep speed and vertical gain are as shown
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neuromuscular transmission defect, but in human SPS,
the effect of GAD antibodies is still unknown in the
neuromuscular junction.
To date, GAD antibodies have been found in increased
titer in Miller Fisher syndrome, a condition with a pre-
synaptic neuromuscular transmission defect [14], and
myasthenia gravis [15], where the defect occurs at the
postsynaptic region. Hence, the effect of GAD anti-
bodies may not be limited only to a single location in
the nervous system.
Conversely, other autoantibodies against amphiphysin
and gephyrin [16] have been reported in SPS. Their
immunological effects on the central and peripheral
nervous system remain to be seen in this condition.
To our knowledge, this is the first report of presynap-
tic neuromuscular transmission defect occurring in a pa-
tient with chronic SPS. It follows that the diagnoses of
CFS, myalgic encephalomyelitis and fibromyalgia are rea-
sonable differentials here which justify further research
into the role of neuromuscular transmission derange-
ments in their respective pathophysiology.
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